Treatment of cancer by targeting molecules that influence mst1/stk4 signaling
AssigneeCedars-Sinai Medical Center
InventorsBekir Cinar, Filiz Kisaayak Collak
Life of this patent
Estimating the term…
Abstract
The invention relates to the treatment of prostate cancer. In various embodiments, the invention teaches a method of administering one or more compounds that inhibit a molecule that antagonizes the activity of tumor suppressor Mst1 and Mst2 pathway signaling. In certain embodiments, one or more of the compounds include an mTOR and PI3K inhibitor.
Claims33
A method of preventing cancer in an individual, comprising:
- providing one or more compositions that directly or indirectly inhibit mTOR activity and PI3K activity;
- and
- administering a therapeutically effective amount of one or more of the compositions to the individual so as to prevent cancer in the individual.
A method of inhibiting cancer in an individual, comprising:
- providing one or more compositions that directly or indirectly inhibit mTOR activity and PI3K activity;
- and
- administering a therapeutically effective amount of one or more of the compositions to the individual so as to inhibit cancer in the individual.
A method of treating cancer in an individual, comprising:
- providing one or more compositions that directly or indirectly inhibit mTOR activity and PI3K activity;
- and
- administering a therapeutically effective amount of one or more of the compositions to the individual so as to treat cancer in the individual.
A method of reducing a rate of cancer tumor development and/or progression to a metastatic state in an individual, comprising:
- providing one or more compositions that directly or indirectly inhibit mTOR activity and PI3K activity;
- and
- administering a therapeutically effective amount of one or more of the compositions to the individual, so as to reduce the rate of cancer tumor development and/or progression to the metastatic state in the individual.
A kit for treating, inhibiting or preventing a cancer in a subject in need thereof, comprising:
- (i) providing one or more compositions that directly or indirectly inhibit mTOR activity and PI3K activity;
- and
- (ii) instructions for the use of the one or more compositions for treating, preventing or inhibiting the cancer in the individual.
Dependencies are inferred from the claim text.